deltatrials

Carcinoma, non-small-cell lung Trials in Tel Aviv, Israel

Conditions / Carcinoma, non-small-cell lung / Tel Aviv, Israel

Carcinoma, non-small-cell lung is a medical condition with active clinical research programs worldwide.

24 total trials for this combination

Showing top 10 of 24 trials

Trials

NCT ID Title Status Phase
NCT02395172 Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) COMPLETED PHASE3
NCT06868277 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer RECRUITING
NCT06012435 A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) ACTIVE_NOT_RECRUITING PHASE3
NCT06868277 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer RECRUITING
NCT04988295 A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure ACTIVE_NOT_RECRUITING
NCT02414139 Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) COMPLETED PHASE2
NCT03833154 Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation ACTIVE_NOT_RECRUITING
NCT04538664 A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions ACTIVE_NOT_RECRUITING PHASE3
NCT04487080 A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING

Related Pages